10 completed, 8 recruiting, 8 terminated, 7 active not recruiting. 26 Phase 1, 16 Phase 2, 1 Not applicable.
Follow Recurrent B-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Recurrent B-Cell Non-Hodgkin Lymphoma trials Research Report on Recurrent B-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-04-28 | 2026-05-27 |
| Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma ONC-PluReceptor NK cells - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-02-24 | 2026-10-07 |
| Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Epcoritamab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Reem Karmali | 34 | 2025-07-25 | 2026-07-08 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy - High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-09-29 | 2026-03-05 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-08-01 | 2026-02-23 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma Selicrelumab, Atezolizumab - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | The Lymphoma Academic Research Organisation | 4 | 2019-07-04 | 2021-07-26 |
Showing 20 of 38. Sign in to see all of them.
Lymphoma, B-Cell (38) · Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma, Mantle-Cell (14) · Lymphoma, Follicular (12) · Burkitt Lymphoma (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, T-Cell (6) · Hodgkin Disease (4) · Waldenstrom Macroglobulinemia (4) · Lymphoma, Non-Hodgkin (3) · Leukemia, Hairy Cell (1) · Leukemia, Lymphoid (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Primary Effusion (1)
Hemic and Lymphatic Diseases (38) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Lymphoma (38) · Lymphoproliferative Disorders (38) · Neoplasms (38) · Neoplasms by Histologic Type (38) · Lymphoma, Non-Hodgkin (35) · Hematologic Diseases (14) · Disease Attributes (10) · Leukemia (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Chronic Disease (9)
Rituximab (9) · Specimen Handling (8) · CT-P10 (7) · Magnetic Resonance Spectroscopy (7) · Biopsy (5) · Cyclophosphamide (5) · Lenalidomide (5) · fludarabine (4) · Etoposide (3) · Leukapheresis (3) · fludarabine phosphate (3) · pembrolizumab (3) · Carmustine (2) · Cytarabine (2) · Hyaluronoglucosaminidase (2)
Fred Hutchinson Cancer Center (7) · National Cancer Institute (NCI) (6) · Mayo Clinic (4) · City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · Academic and Community Cancer Research United (2) · A.O.U. Città della Salute e della Scienza (1) · Barbara Ann Karmanos Cancer Institute (1) · Jonsson Comprehensive Cancer Center (1) · Joseph Tuscano (1) · Kami Maddocks (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Reem Karmali (1) · The Lymphoma Academic Research Organisation (1)
United States (33) · France (1)
Ajay Gopal (4) · Catherine S Diefenbach (3) · Jordan Gauthier (2) · Yago L Nieto (2) · Alex Herrera (1) · Ashley E Rosko, MD (1) · Barbara Botto, MD (1) · Daniel Hommes (1) · Dipenkumar Modi, M.D. (1) · Grzegorz S Nowakowski (1) · Hun Lee (1) · Jennifer E Agrusa, MD (1) · Jennifer E Amengual (1) · Joseph M Tuscano (1) · Joseph Tuscano (1)
PMID 28424162, PMID 31177537, PMID 33785483, PMID 34515338, PMID 39319495, PMID 39820359, PMID 40186077
P01CA044991 (4), P30CA015704 (4), P30CA033572 (4), P30CA015083 (2), P50CA097274 (2), P50CA107399 (2), P01CA229086 (1), P30CA013330 (1), P30CA016058 (1), P30CA016087 (1), P30CA016672 (1), P30CA022453 (1), P30CA060553 (1), P30CA069533 (1), P30CA093373 (1)